Fox Run Management L.L.C. Lowers Holdings in Boston Scientific Co. (NYSE:BSX)

Fox Run Management L.L.C. trimmed its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 28.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,389 shares of the medical equipment provider's stock after selling 3,373 shares during the quarter. Fox Run Management L.L.C.'s holdings in Boston Scientific were worth $749,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Advisors Asset Management Inc. increased its stake in shares of Boston Scientific by 21.3% in the third quarter. Advisors Asset Management Inc. now owns 24,060 shares of the medical equipment provider's stock worth $2,016,000 after buying an additional 4,233 shares during the period. Citizens Financial Group Inc. RI increased its position in shares of Boston Scientific by 41.4% in the third quarter. Citizens Financial Group Inc. RI now owns 5,039 shares of the medical equipment provider's stock valued at $422,000 after acquiring an additional 1,475 shares during the period. Nwam LLC bought a new position in shares of Boston Scientific during the third quarter valued at about $294,000. Great Valley Advisor Group Inc. boosted its holdings in shares of Boston Scientific by 2.7% during the third quarter. Great Valley Advisor Group Inc. now owns 40,455 shares of the medical equipment provider's stock worth $3,390,000 after purchasing an additional 1,074 shares during the period. Finally, Cerity Partners LLC grew its stake in shares of Boston Scientific by 12.7% in the third quarter. Cerity Partners LLC now owns 711,882 shares of the medical equipment provider's stock worth $59,656,000 after purchasing an additional 80,334 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the firm's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares in the company, valued at $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock valued at $14,319,269 in the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of BSX stock traded down $1.51 during trading hours on Friday, reaching $99.29. The company had a trading volume of 7,402,670 shares, compared to its average volume of 6,051,505. The firm has a market cap of $146.86 billion, a PE ratio of 79.43, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The business has a fifty day moving average price of $102.16 and a 200-day moving average price of $93.04. Boston Scientific Co. has a one year low of $66.80 and a one year high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on BSX. Piper Sandler increased their price objective on Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Stifel Nicolaus upped their target price on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a report on Monday, December 16th. Citigroup upped their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Finally, Raymond James lifted their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.